Trial Profile
A Single-centre, Randomized, Double-blind, Dose-ascending, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral TID Doses (One Day) of GSK2982772 in Japanese Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs GSK 2982772 (Primary)
- Indications Autoimmune disorders; Plaque psoriasis; Rheumatoid arthritis; Ulcerative colitis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 09 Nov 2020 Results of pooled analysis of data pooled from two (NCT03305419 and NCT03590613 ) studies comparing the pharmacokinetics of RIPK1 Inhibitor GSK2982772 in healthy Western and Japanese subjects published in the European Journal of Drug Metabolism and Pharmacokinetics
- 25 Jan 2019 Status changed from active, no longer recruiting to completed.
- 16 Aug 2018 Status changed from recruiting to active, no longer recruiting.